InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Friday, 10/04/2019 8:30:20 AM

Friday, October 04, 2019 8:30:20 AM

Post# of 36
News: $HCM Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma

LONDON, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with relapsed or refractory l...

Find out more HCM - Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HCM News